A

mid rising concern over drug-resistant superbugs, Novartis (NVS) is ending research into antibiotics and antivirals because these programs are not a “long-term strategic fit.”

As a result, the company will eliminate 140 jobs from the San Francisco Bay area, where the work is based, although a Novartis spokesman noted the company will continue to research tropical diseases, such as malaria. And he added that the company’s Sandoz generic unit continues to manufacture and supply many such medicines.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy